Cas No.: | 1675201-83-8 |
Chemical Name: | (2S)-1-[[2,6-Dimethoxy-4-[(2-methyl[1,1'-biphenyl]-3-yl)methoxy]phenyl]methyl]-2-piperidinecarboxylic acid |
Synonyms: | PD1/PDL1 inhibitor 1,PD 1/PD L1 inhibitor 1;BMS-1,BMS1,BMS 1 |
SMILES: | CC1=C(C=CC=C1COC2=CC(=C(C(=C2)OC)CN3CCCC[C@H]3C(=O)O)OC)C4=CC=CC=C4 |
Formula: | C29H33NO5 |
M.Wt: | 475.58 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Publication: | [1]. Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4. [2]. Li K, et al. Development of small-molecule i |
Description: | PD-1/PD-L1 inhibitor C1 is a potent and selective small molecule inhibitor of the PD-1/PD-L1 protein/protein interactions with IC50 < 100 nM (PD-1/PD-L1 Homogenous Time-Resolved Fluorescence (HTRF) binding assay). It may potentially be useful in the treatment of cancer as well as infectious diseases such as hepatitis C. The programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction plays a dominant role in the suppression of T cell responses, especially in a tumor microenvironment, protecting tumor cells from lysis,a useful compound immunomodulator compound. |